Chardan Capital Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: Chardan Capital
Rating: 2.7
Author: MarketBeat

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Chardan Capital. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Chardan Capital.

Company	Current Price	Rating Date	Action	Brokerage	Analyst	Rating	Price Target	Impact on Price	Details
OCS Oculis	$12.59 -0.5%	12/5/2023	Initiated by	Chardan Capital	Analyst D. Gataulin	Buy	$30.00	Low	View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 12/5/2023
LXEO Lexeo Therapeutics	$16.83 -1.0%	11/28/2023	Initiated by	Chardan Capital	Analyst G. Livshits	Buy	$23.00	Low	View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023
LICY Li-Cycle	$0.40 +2.6%	11/16/2023	Downgraded by	Chardan Capital	-	Buy -> Neutral		Low	View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 11/16/2023
PRQR ProQR Therapeutics	$2.10 +1.9%	11/8/2023	Upgraded by	Chardan Capital	Analyst K. Nakae	Neutral -> Buy	$2.00	Low	View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 11/8/2023
WBX Wallbox	$1.53 +6.3%	10/19/2023	Downgraded by	Chardan Capital	-	Buy -> Neutral	$2.25	Low	View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 10/19/2023
VYGR Voyager Therapeutics	$7.48 +0.7%	9/18/2023	Reiterated by	Chardan Capital	Analyst G. Livshits	Neutral		Low	View details for Chardan Capital rating of Voyager Therapeutics (NASDAQ:VYGR) on 9/18/2023
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
OTLK Outlook Therapeutics	$0.45 +7.2%	8/31/2023	Downgraded by	Chardan Capital	Analyst D. Gataulin	Buy -> Neutral		Low	View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/31/2023
ZURA Zura Bio	$3.92 -2.0%	8/17/2023	Reiterated by	Chardan Capital	Analyst D. Gataulin	Buy		Low	View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 8/17/2023
QURE uniQure	$5.47 -2.5%	8/17/2023	Reiterated by	Chardan Capital	Analyst Y. Livshits	Buy		Low	View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 8/17/2023
PPBT Purple Biotech	$0.78 -1.3%	8/17/2023	Reiterated by	Chardan Capital	Analyst D. Gataulin	Buy		Low	View details for Chardan Capital rating of Purple Biotech (NASDAQ:PPBT) on 8/17/2023
PLBY PLBY Group	$1.21 -2.4%	8/17/2023	Target Lowered by	Chardan Capital	-	Buy -> Buy	$5.00 -> $4.00	Low	View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 8/17/2023
SLN Silence Therapeutics	$21.20 +0.8%	8/17/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$26.00	Low	View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 8/17/2023
IOVA Iovance Biotherapeutics	$8.68 +7.6%	8/16/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$29.00	Low	View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 8/16/2023
LICY Li-Cycle	$0.40 +2.6%	8/16/2023	Target Lowered by	Chardan Capital	-	Buy -> Buy	$8.00 -> $7.00	Low	View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 8/16/2023
VLN Valens Semiconductor	$2.26 +1.8%	8/15/2023	Target Lowered by	Chardan Capital	-	Buy -> Buy	$9.00 -> $5.00	Low	View details for Chardan Capital rating of Valens Semiconductor (NYSE:VLN) on 8/15/2023
SNTI Senti Biosciences	$0.43 -4.4%	8/15/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$6.00	Low	View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 8/15/2023
OTLK Outlook Therapeutics	$0.45 +7.2%	8/15/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$10.00	Low	View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/15/2023
TSHA Taysha Gene Therapies	$1.56 +1.3%	8/15/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$5.00	Low	View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 8/15/2023
TNYA Tenaya Therapeutics	$5.13 +16.1%	8/14/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$23.00	Low	View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/14/2023
GANX Gain Therapeutics	$4.84 +1.9%	8/14/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$6.00	Low	View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 8/14/2023
SYBX Synlogic	$3.45 -2.0%	8/11/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$90.00	Low	View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 8/11/2023
CLSK CleanSpark	$10.50 +12.8%	8/11/2023	Target Raised by	Chardan Capital	-	Buy -> Buy	$10.00 -> $11.00	Low	View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 8/11/2023
MGTX MeiraGTx	$6.29 -2.6%	8/11/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$41.00	Low	View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 8/11/2023
FDMT 4D Molecular Therapeutics	$26.90 -4.7%	8/11/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$31.00	Low	View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 8/11/2023
RCKT Rocket Pharmaceuticals	$29.26 +1.2%	8/11/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$61.00	Low	View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 8/11/2023
FEMY Femasys	$1.38 +17.9%	8/11/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$10.00	Low	View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 8/11/2023
ADVM Adverum Biotechnologies	$1.97 -29.9%	8/11/2023	Upgraded by	Chardan Capital	Analyst D. Gataulin	Neutral -> Buy	$2.00 -> $4.00	Low	View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 8/11/2023
OBIO Orchestra BioMed	$6.95 +2.4%	8/9/2023	Reiterated by	Chardan Capital	Analyst K. Nakae	Buy -> Buy	$20.00	Low	View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 8/9/2023
COYA Coya Therapeutics	$6.81 +6.1%	8/9/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$11.00	Low	View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 8/9/2023
NRGV Energy Vault	$1.66 +5.1%	8/9/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$7.00	Low	View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 8/9/2023
IOVA Iovance Biotherapeutics	$8.68 +7.6%	8/9/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$29.00	Low	View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 8/9/2023
PET Wag! Group	$1.85 -0.5%	8/10/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$8.00	N/A	View details for Chardan Capital rating of Wag! Group (NASDAQ:PET) on 8/10/2023
SLDP Solid Power	$1.60 +3.9%	8/10/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$5.00	N/A	View details for Chardan Capital rating of Solid Power (NASDAQ:SLDP) on 8/10/2023
IPSC Century Therapeutics	$4.45 -2.4%	8/9/2023	Target Lowered by	Chardan Capital	-	Buy -> Buy	$19.00 -> $17.00	Low	View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 8/9/2023
RNA Avidity Biosciences	$12.51 +3.0%	8/9/2023	Target Lowered by	Chardan Capital	-	Buy -> Buy	$27.00 -> $23.00	Low	View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 8/9/2023
ARWR Arrowhead Pharmaceuticals	$30.85 -2.5%	8/8/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$60.00	Low	View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 8/8/2023
ALNY Alnylam Pharmaceuticals	$169.50 +0.5%	8/8/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$250.00	Low	View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 8/8/2023
CRSP CRISPR Therapeutics	$68.83 +4.7%	8/7/2023	Target Lowered by	Chardan Capital	-	Buy -> Buy	$123.00 -> $110.00	Low	View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/7/2023
KRYS Krystal Biotech	$111.03 -0.1%	8/7/2023	Target Raised by	Chardan Capital	-	Buy -> Buy	$148.00 -> $153.00	Low	View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 8/7/2023
PASG Passage Bio	$0.99 -2.0%	8/7/2023	Target Lowered by	Chardan Capital	-	Buy -> Buy	$11.00 -> $9.00	Low	View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 8/7/2023

MARA Marathon Digital	$21.58 +23.0%	8/7/2023	Downgraded by	Chardan Capital	-	Buy -> Neutral	$15.00	Low	View details for Chardan Capital rating of Marathon Digital (NASDAQ:MARA) on 8/7/2023
NTLA Intellia Therapeutics	$27.47 +5.4%	8/7/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$107.00	Low	View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 8/7/2023
ACHL Achilles Therapeutics	$0.94 +2.2%	8/7/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$11.00	Low	View details for Chardan Capital rating of Achilles Therapeutics (NASDAQ:ACHL) on 8/7/2023
IMRX Immuneering	$6.09 +1.8%	8/7/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$22.00	Low	View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 8/7/2023
ABUS Arbutus Biopharma	$2.54 +2.0%	8/4/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$6.00	Low	View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 8/4/2023
DYN Dyne Therapeutics	$22.73 +6.0%	8/4/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$20.00	Low	View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 8/4/2023
OMGA Omega Therapeutics	$3.60 +0.3%	8/4/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$12.00	Low	View details for Chardan Capital rating of Omega Therapeutics (NASDAQ:OMGA) on 8/4/2023
PRQR ProQR Therapeutics	$2.10 +1.9%	8/4/2023	Reiterated by	Chardan Capital	-	Neutral -> Neutral	$2.00	Low	View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 8/4/2023
MESO Mesoblast	$1.82 +1.7%	8/4/2023	Target Lowered by	Chardan Capital	-	Sell -> Sell	$4.00 -> $3.00	Low	View details for Chardan Capital rating of Mesoblast (NASDAQ:MESO) on 8/4/2023
RGNX REGENXBIO	$16.29 +11.8%	8/3/2023	Reiterated by	Chardan Capital	-	Buy	$55.00	Low	View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 8/3/2023
EYPT EyePoint Pharmaceuticals	$29.12 -0.9%	8/3/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$22.00	Low	View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 8/3/2023
EDIT Editas Medicine	$7.17 +0.8%	8/2/2023	Target Lowered by	Chardan Capital	-	Buy -> Buy	$22.00 -> $19.00	Low	View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 8/2/2023
NRGV Energy Vault	$1.66 +5.1%	8/2/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$7.00	Low	View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 8/2/2023
LICY Li-Cycle	$0.40 +2.6%	8/1/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$8.00	Low	View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 8/1/2023
BMTX BM Technologies	$2.07 +0.5%	7/26/2023	Target Lowered by	Chardan Capital	-	Buy	$13.00 -> $8.00	Low	View details for Chardan Capital rating of BM Technologies (NYSE:BMTX) on 7/26/2023
KOD Kodiak Sciences	$5.27 +11.9%	7/25/2023	Downgraded by	Chardan Capital	Analyst D. Gataulin	Buy -> Neutral		Low	View details for Chardan Capital rating of Kodiak Sciences (NASDAQ:KOD) on 7/25/2023
CLSK CleanSpark	$10.50 +12.8%	7/24/2023	Target Raised by	Chardan Capital	-	Buy	$6.00 -> $10.00	Low	View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 7/24/2023
FBRX Forte Biosciences	$0.63 +6.8%	7/16/2023	Reiterated by	Chardan Capital	Analyst K. Nakae	Neutral		Low	View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 7/16/2023
DFLI Dragonfly Energy	$0.50 +11.1%	7/13/2023	Reiterated by	Chardan Capital	-	Buy -> Buy	$10.00	Low	View details for Chardan Capital rating of Dragonfly Energy (NASDAQ:DFLI) on 7/13/2023
OUST Ouster	$5.06 +2.6%	7/13/2023	Upgraded by	Chardan Capital	-	Neutral -> Buy	$10.00	Low	View details for Chardan Capital rating of Ouster (NYSE:OUST) on 7/13/2023
WBX Wallbox	$1.53 +6.3%	6/30/2023	Target Lowered by	Chardan Capital	-	Buy	$12.00 -> $11.00	Low	View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 6/30/2023
ZURA Zura Bio	$3.92 -2.0%	7/10/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy		Low	View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 7/10/2023
XLO Xilio Therapeutics	$0.60 -9.1%	7/10/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy		Low	View details for Chardan Capital rating of Xilio Therapeutics (NASDAQ:XLO) on 7/10/2023
QURE uniQure	$5.47 -2.5%	7/10/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy		Low	View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 7/10/2023
PPBT Purple Biotech	$0.78 -1.3%	7/10/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy		Low	View details for Chardan Capital rating of Purple Biotech (NASDAQ:PPBT) on 7/10/2023
IMVT Immunovant	$35.27 +0.1%	7/10/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy		Low	View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 7/10/2023
IMNM Immunome	$23.49 -5.7%	7/10/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy		Low	View details for Chardan Capital rating of Immunome (NASDAQ:IMNM) on 7/10/2023
FIXX Homology Medicines	$0.71 -1.4%	7/10/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy		Low	View details for Chardan Capital rating of Homology Medicines (NASDAQ:FIXX) on 7/10/2023
FDMT 4D Molecular Therapeutics	$26.90 -4.7%	7/11/2023	Target Raised by	Chardan Capital	-		$30.00 -> $31.00	Low	View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 7/11/2023
FDMT 4D Molecular Therapeutics	$26.90 -4.7%	7/5/2023	Initiated by	Chardan Capital	-	Buy	$30.00	Low	View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 7/5/2023
ZURA Zura Bio	$3.92 -2.0%	6/14/2023	Initiated by	Chardan Capital	Analyst M. Barcus	Buy	$14.00	Low	View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 6/14/2023
NTLA Intellia Therapeutics	$27.47 +5.4%	6/13/2023	Target Lowered by	Chardan Capital	-		$111.00 -> $107.00	Low	View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 6/13/2023
COYA Coya Therapeutics	$6.81 +6.1%	6/7/2023	Target Raised by	Chardan Capital	Analyst K. Nakae		$9.00 -> $11.00	Low	View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 6/7/2023
SYBX Synlogic	$3.45 -2.0%	6/6/2023	Target Raised by	Chardan Capital	-		$82.50 -> $90.00	Low	View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 6/6/2023
PRST Presto Automation	$0.19 +19.3%	6/1/2023	Upgraded by	Chardan Capital	-	Neutral -> Buy	$4.25 -> $5.00	N/A	View details for Chardan Capital rating of Presto Automation (NASDAQ:PRST) on 6/1/2023
MESO Mesoblast	$1.82 +1.7%	5/30/2023	Target Lowered by	Chardan Capital	-		$5.00 -> $4.00	Low	View details for Chardan Capital rating of Mesoblast (NASDAQ:MESO) on 5/30/2023
IMVT Immunovant	$35.27 +0.1%	5/22/2023	Target Raised by	Chardan Capital	-		$21.00 -> $32.00	Low	View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 5/22/2023
KRYS Krystal Biotech	$111.03 -0.1%	5/22/2023	Target Raised by	Chardan Capital	-		$133.00 -> $148.00	Low	View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 5/22/2023
EYPT EyePoint Pharmaceuticals	$29.12 -0.9%	5/18/2023	Target Raised by	Chardan Capital	-		$21.00 -> $22.00	Low	View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 5/18/2023
FBRX Forte Biosciences	$0.63 +6.8%	5/15/2023	Reiterated by	Chardan Capital	Analyst K. Nakae	Neutral		Low	View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 5/15/2023
KITT Nauticus Robotics	$0.35 +3.0%	5/12/2023	Downgraded by	Chardan Capital	-	Buy -> Neutral	$2.50	Low	View details for Chardan Capital rating of Nauticus Robotics (NASDAQ:KITT) on 5/12/2023
TNYA Tenaya Therapeutics	$5.13 +16.1%	5/11/2023	Target Lowered by	Chardan Capital	-		$24.00 -> $23.00	Low	View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 5/11/2023
VLN Valens Semiconductor	$2.26 +1.8%	5/11/2023	Target Lowered by	Chardan Capital	-	Buy	$13.00 -> $12.00	Low	View details for Chardan Capital rating of Valens Semiconductor (NYSE:VLN) on 5/11/2023
QURE uniQure	$5.47 -2.5%	5/10/2023	Target Lowered by	Chardan Capital	-		$60.00 -> $56.00	Low	View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 5/10/2023
OCGN Ocugen	$0.52 -1.9%	5/7/2023	Target Raised by	Chardan Capital	Analyst D. Gataulin		$3.50 -> $4.00	Low	View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 5/7/2023
RCKT Rocket Pharmaceuticals	$29.26 +1.2%	5/5/2023	Target Lowered by	Chardan Capital	-		$63.00 -> $61.00	Low	View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/5/2023
RGNX REGENXBIO	$16.29 +11.8%	5/4/2023	Target Lowered by	Chardan Capital	-		$61.00 -> $55.00	Low	View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 5/4/2023
MCRB Seres Therapeutics	$1.04 +1.0%	4/28/2023	Target Lowered by	Chardan Capital	-		$12.00 -> $10.00	Low	View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 4/28/2023
WBX Wallbox	$1.53 +6.3%	4/18/2023	Reiterated by	Chardan Capital	-	Buy	$12.00	Low	View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 4/18/2023
IMRX Immuneering	$6.09 +1.8%	4/18/2023	Target Raised by	Chardan Capital	-	Buy	$18.00 -> $22.00	Low	View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 4/18/2023

OCGN Ocugen	$0.52 -1.9%	4/14/2023	Reiterated by	Chardan Capital	Analyst D. Gataulin	Buy	$3.50	Low	View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 4/14/2023
CLSK CleanSpark	$10.50 +12.8%	4/17/2023	Reiterated by	Chardan Capital	-	Buy	$5.00	Low	View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 4/17/2023
MARA Marathon Digital	$21.58 +23.0%	4/3/2023	Reiterated by	Chardan Capital	-	Buy	$15.00	Low	View details for Chardan Capital rating of Marathon Digital (NASDAQ:MARA) on 4/3/2023
COYA Coya Therapeutics	$6.81 +6.1%	3/30/2023	Reiterated by	Chardan Capital	Analyst K. Nakae	Buy	$9.00	Low	View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/30/2023
RNA Avidity Biosciences	$12.51 +3.0%	3/31/2023	Reiterated by	Chardan Capital	-	Buy	$27.00	N/A	View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 3/31/2023
FEMY Femasys	$1.38 +17.9%	3/30/2023	Target Lowered by	Chardan Capital	-	Buy	$12.00 -> $10.00	Low	View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 3/30/2023
TSHA Taysha Gene Therapies	$1.56 +1.3%	3/29/2023	Target Lowered by	Chardan Capital	-	Buy	$6.00 -> $5.00	Low	View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 3/29/2023
SYBX Synlogic	$3.45 -2.0%	3/29/2023	Target Lowered by	Chardan Capital	-	Buy	$105.00 -> $82.50	Low	View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 3/29/2023
PRST Presto Automation	$0.19 +19.3%	3/28/2023	Reiterated by	Chardan Capital	-	Neutral	$4.25	N/A	View details for Chardan Capital rating of Presto Automation (NASDAQ:PRST) on 3/28/2023
MARA Marathon Digital	$21.58 +23.0%	3/28/2023	Target Lowered by	Chardan Capital	-	Buy	$17.00 -> $15.00	Low	View details for Chardan Capital rating of Marathon Digital (NASDAQ:MARA) on 3/28/2023
BMTX BM Technologies	$2.07 +0.5%	3/29/2023	Reiterated by	Chardan Capital	-	Buy	$13.00	Low	View details for Chardan Capital rating of BM Technologies (NYSE:BMTX) on 3/29/2023
GANX Gain Therapeutics	$4.84 +1.9%	3/27/2023	Target Raised by	Chardan Capital	-		$4.00 -> $5.75	Low	View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 3/27/2023
OUST Ouster	$5.06 +2.6%	3/24/2023	Downgraded by	Chardan Capital	-	Buy -> Neutral	$10.00	Low	View details for Chardan Capital rating of Ouster (NYSE:OUST) on 3/24/2023
SNTI Senti Biosciences	$0.43 -4.4%	3/23/2023	Target Lowered by	Chardan Capital	-	Buy	$8.00 -> $7.00	Low	View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 3/23/2023
IMTX Immatics	$11.30 +1.3%	3/23/2023	Target Lowered by	Chardan Capital	-	Buy	$28.00 -> $25.00	Low	View details for Chardan Capital rating of Immatics (NASDAQ:IMTX) on 3/23/2023
COYA Coya Therapeutics	$6.81 +6.1%	3/22/2023	Reiterated by	Chardan Capital	Analyst K. Nakae	Buy	$9.00	Low	View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/22/2023
ANIX Anixa Biosciences	$4.48 +0.4%	3/22/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy	$8.00 -> $9.00	Low	View details for Chardan Capital rating of Anixa Biosciences (NASDAQ:ANIX) on 3/22/2023
CABA Cabaletta Bio	$25.38 +7.6%	3/22/2023	Reiterated by	Chardan Capital	-	Buy	$12.00	Low	View details for Chardan Capital rating of Cabaletta Bio (NASDAQ:CABA) on 3/22/2023
IPSC Century Therapeutics	$4.45 -2.4%	3/22/2023	Reiterated by	Chardan Capital	Analyst G. Livshits	Buy	$19.00	Low	View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 3/22/2023
IMNM Immunome	$23.49 -5.7%	3/16/2023	Target Lowered by	Chardan Capital	-	Buy	$9.00 -> $8.00	Low	View details for Chardan Capital rating of Immunome (NASDAQ:IMNM) on 3/16/2023
MGTX MeiraGTx	$6.29 -2.6%	3/16/2023	Target Lowered by	Chardan Capital	-	Buy	$47.00 -> $41.00	Low	View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 3/16/2023
SLN Silence Therapeutics	$21.20 +0.8%	3/16/2023	Target Lowered by	Chardan Capital	-	Buy	$29.00 -> $26.00	Low	View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 3/16/2023
NRGV Energy Vault	$1.66 +5.1%	3/9/2023	Target Lowered by	Chardan Capital	-	Buy	$13.00 -> $7.00	Low	View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 3/9/2023
TNYA Tenaya Therapeutics	$5.13 +16.1%	3/9/2023	Target Lowered by	Chardan Capital	-	Buy	$28.00 -> $24.00	Low	View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/9/2023
MCRB Seres Therapeutics	$1.04 +1.0%	3/8/2023	Reiterated by	Chardan Capital	-	Buy	$12.00	Low	View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 3/8/2023
ACHL Achilles Therapeutics	$0.94 +2.2%	3/8/2023	Target Lowered by	Chardan Capital	-		$17.00 -> $12.00	Low	View details for Chardan Capital rating of Achilles Therapeutics (NASDAQ:ACHL) on 3/8/2023
IMRX Immuneering	$6.09 +1.8%	3/7/2023	Reiterated by	Chardan Capital	-	Buy	$18.00	N/A	View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 3/7/2023
EYPT EyePoint Pharmaceuticals	$29.12 -0.9%	3/3/2023	Reiterated by	Chardan Capital	-	Buy	$21.00	Low	View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 3/3/2023
GWH ESS Tech	$0.94 +3.3%	3/3/2023	Target Lowered by	Chardan Capital	-	Neutral	$4.50 -> $1.80	Low	View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 3/3/2023
VLN Valens Semiconductor	$2.26 +1.8%	3/3/2023	Reiterated by	Chardan Capital	-	Buy	$13.00	Low	View details for Chardan Capital rating of Valens Semiconductor (NYSE:VLN) on 3/3/2023
ABUS Arbutus Biopharma	$2.54 +2.0%	3/3/2023	Reiterated by	Chardan Capital	-	Buy	$6.00	Low	View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 3/3/2023
DYN Dyne Therapeutics	$22.73 +6.0%	3/3/2023	Target Raised by	Chardan Capital	-	Buy	$17.00 -> $20.00	Low	View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/3/2023
RGNX REGENXBIO	$16.29 +11.8%	3/2/2023	Reiterated by	Chardan Capital	-	Buy	$61.00	Low	View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 3/2/2023
IOVA Iovance Biotherapeutics	$8.68 +7.6%	3/1/2023	Reiterated by	Chardan Capital	Analyst Geulah Livshits	Buy	$29.00	Low	View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 3/1/2023
MESO Mesoblast	$1.82 +1.7%	3/1/2023	Reiterated by	Chardan Capital	-	Sell	$5.00	Low	View details for Chardan Capital rating of Mesoblast (NASDAQ:MESO) on 3/1/2023
RNA Avidity Biosciences	$12.51 +3.0%	3/1/2023	Reiterated by	Chardan Capital	-	Buy	$27.00	Low	View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 3/1/2023
OCGN Ocugen	$0.52 -1.9%	3/1/2023	Upgraded by	Chardan Capital	Analyst D. Gataulin	Neutral -> Buy	$3.50	Low	View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/1/2023
RCKT Rocket Pharmaceuticals	$29.26 +1.2%	3/1/2023	Target Lowered by	Chardan Capital	-	Buy	$65.00 -> $63.00	Low	View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 3/1/2023
KRYS Krystal Biotech	$111.03 -0.1%	2/28/2023	Reiterated by	Chardan Capital	-	Buy	$133.00	Low	View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 2/28/2023
QURE uniQure	$5.47 -2.5%	2/28/2023	Reiterated by	Chardan Capital	-	Buy	$60.00	Low	View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 2/28/2023
LICY Li-Cycle	$0.40 +2.6%	2/28/2023	Reiterated by	Chardan Capital	-	Buy	$10.00	Low	View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 2/28/2023
NTLA Intellia Therapeutics	$27.47 +5.4%	2/24/2023	Target Lowered by	Chardan Capital	Analyst Geulah Livshits	Buy	$129.00 -> $111.00	Low	View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/24/2023
WBX Wallbox	$1.53 +6.3%	2/24/2023	Target Lowered by	Chardan Capital	-	Buy	$13.00 -> $12.00	Low	View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 2/24/2023
ALNY Alnylam Pharmaceuticals	$169.50 +0.5%	2/24/2023	Reiterated by	Chardan Capital	-	Buy	$250.00	Low	View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/24/2023
EDIT Editas Medicine	$7.17 +0.8%	2/23/2023	Target Lowered by	Chardan Capital	-	Buy	$35.00 -> $22.00	Low	View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 2/23/2023
PET Wag! Group	$1.85 -0.5%	2/22/2023	Target Raised by	Chardan Capital	-	Buy	$5.00 -> $8.00	Low	View details for Chardan Capital rating of Wag! Group (NASDAQ:PET) on 2/22/2023
CRSP CRISPR Therapeutics	$68.83 +4.7%	2/22/2023	Target Lowered by	Chardan Capital	-	Buy	$153.00 -> $123.00	Low	View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/22/2023
PRST Presto Automation	$0.19 +19.3%	2/16/2023	Reiterated by	Chardan Capital	-	Neutral	$4.25	N/A	View details for Chardan Capital rating of Presto Automation (NASDAQ:PRST) on 2/16/2023
PLBY PLBY Group	$1.21 -2.4%	2/13/2023	Reiterated by	Chardan Capital	-	Buy	$5.00	Low	View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 2/13/2023
DFLI Dragonfly Energy	$0.50 +11.1%	2/10/2023	Target Lowered by	Chardan Capital	-	Buy	$15.00 -> $10.00	Low	View details for Chardan Capital rating of Dragonfly Energy (NASDAQ:DFLI) on 2/10/2023

ARWR Arrowhead Pharmaceuticals	$30.85 -2.5%	2/10/2023	Reiterated by	Chardan Capital	-	Buy	$60.00	Low	View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/10/2023
PPBT Purple Biotech	$0.78 -1.3%	2/9/2023	Reiterated by	Chardan Capital	Analyst M. Barcus	Buy	$11.00	Low	View details for Chardan Capital rating of Purple Biotech (NASDAQ:PPBT) on 2/9/2023
BMTX BM Technologies	$2.07 +0.5%	2/7/2023	Target Lowered by	Chardan Capital	-	Buy	$21.00 -> $13.00	Low	View details for Chardan Capital rating of BM Technologies (NYSE:BMTX) on 2/7/2023
OBIO Orchestra BioMed	$6.95 +2.4%	2/7/2023	Initiated by	Chardan Capital	Analyst K. Nakae	Buy	$20.00	Low	View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 2/7/2023
IMVT Immunovant	$35.27 +0.1%	2/5/2023	Target Raised by	Chardan Capital	-	Buy	$19.00 -> $21.00	Low	View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 2/5/2023
TSHA Taysha Gene Therapies	$1.56 +1.3%	2/1/2023	Target Lowered by	Chardan Capital	-	Buy	$16.00 -> $6.00	Low	View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 2/1/2023
LICY Li-Cycle	$0.40 +2.6%	1/31/2023	Target Lowered by	Chardan Capital	-	Buy	$13.00 -> $10.00	Low	View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 1/31/2023
SNTI Senti Biosciences	$0.43 -4.4%	1/27/2023	Target Lowered by	Chardan Capital	-	Buy	$12.00 -> $8.00	Low	View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 1/27/2023
COYA Coya Therapeutics	$6.81 +6.1%	1/26/2023	Initiated by	Chardan Capital	Analyst K. Nakae	Buy	$9.00	N/A	View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 1/26/2023
MRNA Moderna	$93.66 -5.7%	1/18/2023	Target Raised by	Chardan Capital	Analyst Y. Livshits	Neutral	$191.00 -> $208.00	Low	View details for Chardan Capital rating of Moderna (NASDAQ:MRNA) on 1/18/2023
ARWR Arrowhead Pharmaceuticals	$30.85 -2.5%	1/10/2023	Target Lowered by	Chardan Capital	-		$82.00 -> $60.00	Low	View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 1/10/2023
IPSC Century Therapeutics	$4.45 -2.4%	12/27/2022	Initiated by	Chardan Capital	Analyst G. Livshits	Buy	$19.00	Low	View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 12/27/2022
ANIX Anixa Biosciences	$4.48 +0.4%	12/23/2022	Initiated by	Chardan Capital	-	Buy	$8.00	Low	View details for Chardan Capital rating of Anixa Biosciences (NASDAQ:ANIX) on 12/23/2022
XLO Xilio Therapeutics	$0.60 -9.1%	12/21/2022	Initiated by	Chardan Capital	Analyst M. Barcus	Buy	$7.00	Low	View details for Chardan Capital rating of Xilio Therapeutics (NASDAQ:XLO) on 12/21/2022
CLSK CleanSpark	$10.50 +12.8%	12/15/2022	Target Lowered by	Chardan Capital	-	Buy	$6.00 -> $5.00	Low	View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 12/15/2022
PASG Passage Bio	$0.99 -2.0%	12/15/2022	Target Lowered by	Chardan Capital	-	Buy	$18.00 -> $11.00	Low	View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 12/15/2022
MRNA Moderna	$93.66 -5.7%	12/14/2022	Downgraded by	Chardan Capital	Analyst Y. Livshits	Buy -> Neutral	$186.00 -> $191.00	Low	View details for Chardan Capital rating of Moderna (NASDAQ:MRNA) on 12/14/2022
PRST Presto Automation	$0.19 +19.3%	12/9/2022	Initiated by	Chardan Capital	-	Neutral	$4.25	N/A	View details for Chardan Capital rating of Presto Automation (NASDAQ:PRST) on 12/9/2022
GANX Gain Therapeutics	$4.84 +1.9%	12/9/2022	Initiated by	Chardan Capital	-	Buy	$4.00	Low	View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 12/9/2022
ACHL Achilles Therapeutics	$0.94 +2.2%	12/6/2022	Target Lowered by	Chardan Capital	-	Buy	$20.00 -> $17.00	Low	View details for Chardan Capital rating of Achilles Therapeutics (NASDAQ:ACHL) on 12/6/2022
IOVA Iovance Biotherapeutics	$8.68 +7.6%	11/18/2022	Target Lowered by	Chardan Capital	-	Buy	$30.00 -> $29.00	Low	View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 11/18/2022
DFLI Dragonfly Energy	$0.50 +11.1%	11/18/2022	Initiated by	Chardan Capital	-	Buy	$15.00	Low	View details for Chardan Capital rating of Dragonfly Energy (NASDAQ:DFLI) on 11/18/2022
EDIT Editas Medicine	$7.17 +0.8%	11/17/2022	Target Lowered by	Chardan Capital	-	Buy	$43.00 -> $35.00	Low	View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 11/17/2022
SLN Silence Therapeutics	$21.20 +0.8%	11/17/2022	Target Lowered by	Chardan Capital	-	Buy	$33.00 -> $29.00	Low	View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 11/17/2022
FIXX Homology Medicines	$0.71 -1.4%	11/17/2022	Target Lowered by	Chardan Capital	Analyst M. Barcus	Buy -> Buy	$10.00 -> $8.00	Low	View details for Chardan Capital rating of Homology Medicines (NASDAQ:FIXX) on 11/17/2022
VINC Vincerx Pharma	$1.35 -4.3%	11/16/2022	Target Lowered by	Chardan Capital	-	Buy	$4.00 -> $3.00	Low	View details for Chardan Capital rating of Vincerx Pharma (NASDAQ:VINC) on 11/16/2022
PDSB PDS Biotechnology	$5.26 -0.6%	11/14/2022	Target Raised by	Chardan Capital	-	Buy	$15.00 -> $16.00	Low	View details for Chardan Capital rating of PDS Biotechnology (NASDAQ:PDSB) on 11/14/2022
NTLA Intellia Therapeutics	$27.47 +5.4%	11/14/2022	Target Raised by	Chardan Capital	Analyst Geulah Livshits	Buy	$121.00 -> $129.00	Low	View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 11/14/2022
CABA Cabaletta Bio	$25.38 +7.6%	11/11/2022	Target Lowered by	Chardan Capital	-	Buy	$13.00 -> $12.00	Low	View details for Chardan Capital rating of Cabaletta Bio (NASDAQ:CABA) on 11/11/2022
ADVM Adverum Biotechnologies	$1.97 -29.9%	11/11/2022	Target Lowered by	Chardan Capital	-	Neutral	$2.50 -> $2.00	Low	View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 11/11/2022
TNYA Tenaya Therapeutics	$5.13 +16.1%	11/11/2022	Target Lowered by	Chardan Capital	-	Buy	$30.00 -> $28.00	Low	View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/11/2022
SYBX Synlogic	$3.45 -2.0%	11/11/2022	Target Lowered by	Chardan Capital	Analyst Keay Nakae	Buy	$135.00 -> $105.00	Low	View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 11/11/2022
FEMY Femasys	$1.38 +17.9%	11/11/2022	Target Lowered by	Chardan Capital	-	Buy	$15.00 -> $12.00	Low	View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 11/11/2022
TSHA Taysha Gene Therapies	$1.56 +1.3%	11/9/2022	Target Lowered by	Chardan Capital	-	Buy	$32.00 -> $16.00	Low	View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 11/9/2022
EBS Emergent BioSolutions	$1.68 +12.0%	11/9/2022	Target Lowered by	Chardan Capital	-	Buy	$65.00 -> $55.00	Low	View details for Chardan Capital rating of Emergent BioSolutions (NYSE:EBS) on 11/9/2022
VTRS Viatris	$11.56 -1.5%	11/7/2022	Downgraded by	Chardan Capital	-	Buy -> Neutral		N/A	View details for Chardan Capital rating of Viatris (NASDAQ:VTRS) on 11/7/2022
KRYS Krystal Biotech	$111.03 -0.1%	11/7/2022	Target Raised by	Chardan Capital	-	Buy	$130.00 -> $133.00	Low	View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 11/7/2022
IMVT Immunovant	$35.27 +0.1%	11/7/2022	Target Raised by	Chardan Capital	-	Buy	$12.00 -> $19.00	Low	View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 11/7/2022
MRNA Moderna	$93.66 -5.7%	11/7/2022	Target Lowered by	Chardan Capital	-	Buy	$188.00 -> $186.00	Low	View details for Chardan Capital rating of Moderna (NASDAQ:MRNA) on 11/7/2022
GWH ESS Tech	$0.94 +3.3%	11/4/2022	Target Lowered by	Chardan Capital	-	Neutral	$5.00 -> $4.50	Low	View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 11/4/2022
RGNX REGENXBIO	$16.29 +11.8%	11/4/2022	Target Lowered by	Chardan Capital	-	Buy	$70.00 -> $61.00	Low	View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 11/4/2022
NTLA Intellia Therapeutics	$27.47 +5.4%	11/3/2022	Target Lowered by	Chardan Capital	Analyst Geulah Livshits	Buy	$146.00 -> $121.00	Low	View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 11/3/2022
EDIT Editas Medicine	$7.17 +0.8%	11/2/2022	Target Lowered by	Chardan Capital	-	Buy	$60.00 -> $43.00	Low	View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 11/2/2022
CLSK CleanSpark	$10.50 +12.8%	10/28/2022	Target Lowered by	Chardan Capital	-	Buy	$9.00 -> $6.00	Low	View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 10/28/2022
PLBY PLBY Group	$1.21 -2.4%	10/21/2022	Target Lowered by	Chardan Capital	-	Buy	$9.00 -> $5.00	Low	View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 10/21/2022
KITT Nauticus Robotics	$0.35 +3.0%	10/10/2022	Initiated by	Chardan Capital	-	Buy	$11.00	Low	View details for Chardan Capital rating of Nauticus Robotics (NASDAQ:KITT) on 10/10/2022
RCKT Rocket Pharmaceuticals	$29.26 +1.2%	9/30/2022	Target Raised by	Chardan Capital	-	Buy	$62.00 -> $65.00	Low	View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 9/30/2022
PET Wag! Group	$1.85 -0.5%	9/30/2022	Initiated by	Chardan Capital	-	Buy	$5.00	Low	View details for Chardan Capital rating of Wag! Group (NASDAQ:PET) on 9/30/2022
IMVT Immunovant	$35.27 +0.1%	9/29/2022	Target Lowered by	Chardan Capital	Analyst M. Barcus	Buy	$14.00 -> $12.00	Low	View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 9/29/2022
RNA Avidity Biosciences	$12.51 +3.0%	9/27/2022	Target Lowered by	Chardan Capital	Analyst K. Nakae	Buy	$29.00 -> $27.00	Low	View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 9/27/2022

OMGA Omega Therapeutics	$3.60 +0.3%	9/23/2022	Initiated by	Chardan Capital	-	Buy	$12.00	Low	View details for Chardan Capital rating of Omega Therapeutics (NASDAQ:OMGA) on 9/23/2022
SNTI Senti Biosciences	$0.43 -4.4%	9/22/2022	Initiated by	Chardan Capital	-	Buy	$12.00	Low	View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 9/22/2022
NTLA Intellia Therapeutics	$27.47 +5.4%	9/16/2022	Reiterated by	Chardan Capital	Analyst Geulah Livshits	Buy	$146.00	Low	View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 9/16/2022
LICY Li-Cycle	$0.40 +2.6%	9/15/2022	Target Lowered by	Chardan Capital	-	Buy	$18.00 -> $13.00	Low	View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 9/15/2022
OTLK Outlook Therapeutics	$0.45 +7.2%	9/13/2022	Initiated by	Chardan Capital	-	Buy		Low	View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 9/13/2022
PPBT Purple Biotech	$0.78 -1.3%	9/8/2022	Initiated by	Chardan Capital	Analyst M. Barcus	Buy	$11.00	Low	View details for Chardan Capital rating of Purple Biotech (NASDAQ:PPBT) on 9/8/2022
FBRX Forte Biosciences	$0.63 +6.8%	8/17/2022	Downgraded by	Chardan Capital	Analyst K. Nakae	Buy -> Neutral		Low	View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 8/17/2022
FIXX Homology Medicines	$0.71 -1.4%	8/16/2022	Target Lowered by	Chardan Capital	Analyst M. Barcus	Buy -> Buy	$14.00 -> $10.00	Low	View details for Chardan Capital rating of Homology Medicines (NASDAQ:FIXX) on 8/16/2022
GWH ESS Tech	$0.94 +3.3%	8/15/2022	Target Raised by	Chardan Capital	-	Neutral	$3.50 -> $5.00	Low	View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 8/15/2022
CLSK CleanSpark	$10.50 +12.8%	8/15/2022	Target Raised by	Chardan Capital	-	Buy	$7.00 -> $9.00	Low	View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 8/15/2022
ADVM Adverum Biotechnologies	$1.97 -29.9%	8/12/2022	Target Lowered by	Chardan Capital	Analyst D. Gataulin	Neutral	$3.00 -> $2.50	Low	View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 8/12/2022
MGTX MeiraGTx	$6.29 -2.6%	8/12/2022	Target Raised by	Chardan Capital	Analyst Geulah Livshits	Buy	$46.00 -> $47.00	Low	View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 8/12/2022
TSHA Taysha Gene Therapies	$1.56 +1.3%	8/12/2022	Target Lowered by	Chardan Capital	-	Buy	$34.00 -> $32.00	Low	View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 8/12/2022
SLDB Solid Biosciences	$7.24 -0.1%	8/12/2022	Target Lowered by	Chardan Capital	-	Buy	$105.00 -> $90.00	Low	View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 8/12/2022
CABA Cabaletta Bio	$25.38 +7.6%	8/12/2022	Target Lowered by	Chardan Capital	-	Buy	$17.00 -> $13.00	Low	View details for Chardan Capital rating of Cabaletta Bio (NASDAQ:CABA) on 8/12/2022
PRQR ProQR Therapeutics	$2.10 +1.9%	8/12/2022	Downgraded by	Chardan Capital	Analyst K. Nakae	Buy -> Neutral		Low	View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 8/12/2022
SABS SAB Biotherapeutics	$5.43 -2.0%	8/11/2022	Target Lowered by	Chardan Capital	-	Buy	$7.00 -> $3.00	Low	View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 8/11/2022
TNYA Tenaya Therapeutics	$5.13 +16.1%	8/11/2022	Target Lowered by	Chardan Capital	-	Buy	$31.00 -> $30.00	Low	View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/11/2022
IMTX Immatics	$11.30 +1.3%	8/10/2022	Target Lowered by	Chardan Capital	-	Buy	$30.00 -> $28.00	Low	View details for Chardan Capital rating of Immatics (NASDAQ:IMTX) on 8/10/2022
KOD Kodiak Sciences	$5.27 +11.9%	8/10/2022	Target Lowered by	Chardan Capital	Analyst D. Gataulin	Buy	$19.00 -> $18.00	Low	View details for Chardan Capital rating of Kodiak Sciences (NASDAQ:KOD) on 8/10/2022
PLBY PLBY Group	$1.21 -2.4%	8/10/2022	Target Lowered by	Chardan Capital	-	Buy	$13.00 -> $9.00	Low	View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 8/10/2022
QURE uniQure	$5.47 -2.5%	8/9/2022	Target Lowered by	Chardan Capital	Analyst M. Barcus	Buy	$65.00 -> $60.00	Low	View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 8/9/2022
CRSP CRISPR Therapeutics	$68.83 +4.7%	8/9/2022	Target Lowered by	Chardan Capital	-	Buy	$164.00 -> $154.00	Low	View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/9/2022
KRYS Krystal Biotech	$111.03 -0.1%	8/9/2022	Target Lowered by	Chardan Capital	-	Buy	$137.00 -> $130.00	Low	View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 8/9/2022
ARWR Arrowhead Pharmaceuticals	$30.85 -2.5%	8/5/2022	Target Raised by	Chardan Capital	-		$80.00 -> $82.00	Low	View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 8/5/2022
IOVA Iovance Biotherapeutics	$8.68 +7.6%	8/5/2022	Target Lowered by	Chardan Capital	-		$31.00 -> $30.00	Low	View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 8/5/2022
PASG Passage Bio	$0.99 -2.0%	8/5/2022	Target Lowered by	Chardan Capital	-		$34.00 -> $18.00	Low	View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 8/5/2022
NTLA Intellia Therapeutics	$27.47 +5.4%	8/5/2022	Target Lowered by	Chardan Capital	-	Buy	$172.00 -> $146.00	Low	View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 8/5/2022
MCRB Seres Therapeutics	$1.04 +1.0%	8/4/2022	Target Lowered by	Chardan Capital	-		$16.00 -> $12.00	Low	View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 8/4/2022
ALNY Alnylam Pharmaceuticals	$169.50 +0.5%	8/4/2022	Target Raised by	Chardan Capital	Analyst Keay Nakae	Buy	$200.00 -> $250.00	Low	View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 8/4/2022
PLBY PLBY Group	$1.21 -2.4%	8/3/2022	Target Lowered by	Chardan Capital	-	Buy	$21.00 -> $13.00	Low	View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 8/3/2022
DYN Dyne Therapeutics	$22.73 +6.0%	7/20/2022	Initiated by	Chardan Capital	-	Buy	$17.00	Low	View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 7/20/2022
RNA Avidity Biosciences	$12.51 +3.0%	7/20/2022	Initiated by	Chardan Capital	Analyst K. Nakae	Buy	$29.00	Low	View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 7/20/2022
IMRX Immuneering	$6.09 +1.8%	7/8/2022	Initiated by	Chardan Capital	-	Buy	$18.00	N/A	View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 7/8/2022
EYPT EyePoint Pharmaceuticals	$29.12 -0.9%	7/7/2022	Initiated by	Chardan Capital	Analyst D. Gataulin	Buy	$21.00	N/A	View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 7/7/2022
SLDP Solid Power	$1.60 +3.9%	6/29/2022	Initiated by	Chardan Capital	-	Buy	$8.00	Low	View details for Chardan Capital rating of Solid Power (NASDAQ:SLDP) on 6/29/2022
NRGV Energy Vault	$1.66 +5.1%	6/29/2022	Initiated by	Chardan Capital	-	Buy	$13.00	Low	View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 6/29/2022
GWH ESS Tech	$0.94 +3.3%	6/29/2022	Initiated by	Chardan Capital	-	Neutral	$3.50	Low	View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 6/29/2022
CRSP CRISPR Therapeutics	$68.83 +4.7%	6/22/2022	Target Lowered by	Chardan Capital	-	Buy	$168.00 -> $164.00	Low	View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 6/22/2022
SYBX Synlogic	$3.45 -2.0%	6/10/2022	Reiterated by	Chardan Capital	Analyst Keay Nakae	Buy	$135.00	High	View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 6/10/2022
VINC Vincerx Pharma	$1.35 -4.3%	6/7/2022	Target Lowered by	Chardan Capital	Analyst M. Barcus	Buy	$11.00 -> $4.00	High	View details for Chardan Capital rating of Vincerx Pharma (NASDAQ:VINC) on 6/7/2022
MESO Mesoblast	$1.82 +1.7%	6/3/2022	Target Lowered by	Chardan Capital	-	Sell	$13.00 -> $5.00	Low	View details for Chardan Capital rating of Mesoblast (NASDAQ:MESO) on 6/3/2022
MARA Marathon Digital	$21.58 +23.0%	6/3/2022	Initiated by	Chardan Capital	-	Buy	$19.00	Low	View details for Chardan Capital rating of Marathon Digital (NASDAQ:MARA) on 6/3/2022
CLSK CleanSpark	$10.50 +12.8%	6/3/2022	Initiated by	Chardan Capital	-	Buy	$12.00	Low	View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 6/3/2022
IOVA Iovance Biotherapeutics	$8.68 +7.6%	5/27/2022	Target Lowered by	Chardan Capital	-	Buy	$44.00 -> $31.00	High	View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/27/2022
RCKT Rocket Pharmaceuticals	$29.26 +1.2%	5/19/2022	Target Raised by	Chardan Capital	-	Buy	$60.00 -> $62.00	High	View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/19/2022
TSHA Taysha Gene Therapies	$1.56 +1.3%	5/17/2022	Target Lowered by	Chardan Capital	-		$37.00 -> $34.00	Medium	View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 5/17/2022
FIXX Homology Medicines	$0.71 -1.4%	5/17/2022	Target Lowered by	Chardan Capital	Analyst M. Barcus	NA	$14.00	High	View details for Chardan Capital rating of Homology Medicines (NASDAQ:FIXX) on 5/17/2022
MGTX MeiraGTx	$6.29 -2.6%	5/13/2022	Reiterated by	Chardan Capital	Analyst Geulah Livshits	Buy	$46.00	Medium	View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 5/13/2022
SABS SAB Biotherapeutics	$5.43 -2.0%	5/13/2022	Target Lowered by	Chardan Capital	Analyst K. Nakae		$10.00 -> $7.00	High	View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 5/13/2022
IMNM Immunome	$23.49 -5.7%	5/13/2022	Target Lowered by	Chardan Capital	-		$16.00 -> $9.00	High	View details for Chardan Capital rating of Immunome (NASDAQ:IMNM) on 5/13/2022
CRSP CRISPR Therapeutics	$68.83 +4.7%	5/10/2022	Target Lowered by	Chardan Capital	-		$171.00 -> $168.00	High	View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 5/10/2022
OCGN Ocugen	$0.52 -1.9%	5/9/2022	Target Lowered by	Chardan Capital	Analyst D. Gataulin	Neutral -> Neutral	$4.00 -> $3.50	High	View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 5/9/2022
EBS Emergent BioSolutions	$1.68 +12.0%	4/29/2022	Target Lowered by	Chardan Capital	-		$75.00 -> $65.00	High	View details for Chardan Capital rating of Emergent BioSolutions (NYSE:EBS) on 4/29/2022
SLDB Solid Biosciences	$7.24 -0.1%	4/28/2022	Target Lowered by	Chardan Capital	-		$255.00 -> $105.00	High	View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 4/28/2022
PRQR ProQR Therapeutics	$2.10 +1.9%	4/14/2022	Target Lowered by	Chardan Capital	-	Buy	$8.00 -> $2.50	High	View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 4/14/2022
RGNX REGENXBIO	$16.29 +11.8%	4/11/2022	Reiterated by	Chardan Capital	Analyst D. Gataulin	Buy		Medium	View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 4/11/2022
KOD Kodiak Sciences	$5.27 +11.9%	4/11/2022	Reiterated by	Chardan Capital	Analyst D. Gataulin	Buy		High	View details for Chardan Capital rating of Kodiak Sciences (NASDAQ:KOD) on 4/11/2022
ADVM Adverum Biotechnologies	$1.97 -29.9%	4/11/2022	Reiterated by	Chardan Capital	Analyst D. Gataulin	Neutral		Medium	View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 4/11/2022
OCGN Ocugen	$0.52 -1.9%	4/11/2022	Reiterated by	Chardan Capital	Analyst D. Gataulin	Neutral		High	View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 4/11/2022

MarketBeat Community Rating for Chardan Capital

Community Ranking:		2.7 out of 5 ( 2.7 of 5 stars)
Outperform Votes:		22,972 (Vote Outperform)
Underperform Votes:		19,666 (Vote Underperform)
Total Votes:		42,638

MarketBeat's community ratings are surveys of what our community members think about Chardan Capital and other research firms. Vote "Outperform" if you believe Chardan Capital's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Chardan Capital's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Chardan Capital Analyst Recommendations & Stock Picks

MarketBeat Community Rating for Chardan Capital

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info